Information Provided By: 
Fly News Breaks for January 23, 2019
IMMU
Jan 23, 2019 | 09:03 EDT
B. Riley FBR analyst Harshita Polishetty lowered her price target on Immunomedics shares to $28 from $55 and pushed back her expectations for a launch of IMMU-132 in third-line TNBC by one year after the company announced that it received a Complete Response Letter from the FDA. While the CRL "obfuscates" the regulatory pathway and launch timelines for IMMU-132, Polishetty keeps a Buy rating on the shares, citing the potential opportunity in third-line TNBC and other solid cancers.
News For IMMU From the Last 2 Days
There are no results for your query IMMU
